Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 2Phase 4 1Phase 2/3 1Phase 1/2 1

Status

Completed 29Recruiting 5Unknown 3Terminated 2Withdrawn 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Other solid neoplasm 1

Conditions

Sarcoma 1Mesothelioma, Malignant 1Ichthyosis, X-Linked 1

Interventions

Cyclophosphamide 166Docetaxel 154Bevacizumab 153Carboplatin 148Gemcitabine 146Cisplatin 146pembrolizumab 142Radiotherapy 135Paclitaxel 132Capecitabine 122Rituximab 115Oxaliplatin 104Fluorouracil 103Nivolumab 94Irinotecan 85Doxorubicin 85Pemetrexed 83Leucovorin 82Dexamethasone 82fludarabine 74fludarabine phosphate 72Bortezomib 69Etoposide 67Erlotinib Hydrochloride 66Cetuximab 65Methotrexate 58Trastuzumab 56Cytarabine 54Lenalidomide 50Everolimus 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Terminated × Trabectedin × Clear all
NCT01104298 2015-10-27

Doxorubicin vs. Trabectedin Plus Doxorubicin in Non Operable and/or Metastatic STS

Grupo Espanol de Investigacion en Sarcomas

Phase 2 Terminated
115 enrolled
Sarcoma

Sarcoma, Ichthyosis, X-Linked

NCT00027508 2015-02-24

Ecteinascidin 743 in Treating Patients With Malignant Mesothelioma

PharmaMar

Phase 2 Terminated
Other solid neoplasmThoracic

Mesothelioma, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡